Barakat Thabet, MD
Rheumatology · Grand Rapids, MINPI 1184979577
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,975 of the $128,489 with a category attached, or 68.5%. AbbVie accounts for 64.3% of it on its own, with 24 other manufacturers making up the rest. Among rheumatology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 913 payments — averaging $140.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$83K
- GSK$34K
- Johnson & Johnson$5K
- Amgen$3K
- AstraZeneca$1K
- Novartis$719
- plus $2K from 19 others
What the payments were for
- Consulting fees$11,4989%
- Speaking & faculty fees$87,97568%
- Travel & lodging$13,33910%
- Food & beverage$15,13212%
- Education$5460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 291 | $82,557 |
| GSK | 24 | $33,648 |
| Johnson & Johnson(3 entities) | 200 | $4,735 |
| Amgen | 195 | $3,030 |
| AstraZeneca(2 entities) | 40 | $1,408 |
| Novartis | 42 | $719 |
| Pfizer | 38 | $525 |
| Lilly USA, LLC | 14 | $276 |
| UCB, Inc. | 12 | $255 |
| E.r. Squibb & Sons, L.L.C. | 7 | $184 |
| Fresenius Kabi USA, LLC | 7 | $170 |
| Organon | 17 | $164 |
| Aurinia Pharma U.S., Inc. | 3 | $162 |
| Boehringer Ingelheim | 5 | $135 |
| Stryker | 1 | $134 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $91 |
| Genentech USA, Inc. | 2 | $68 |
| Sobi, Inc | 3 | $60 |
| Radius Health, Inc. | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Kaleo, Inc. | 1 | $20 |
| Sandoz | 1 | $19 |
| Alvogen Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$128,489 in reported general payments places this provider in the 95th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 183 | $1,379,486 |
| Humira(Cf) PenAdalimumab | 180 | $1,275,259 |
| RinvoqUpadacitinib | 90 | $597,545 |
| EnbrelEtanercept | 27 | $200,603 |
| Orencia ClickjectAbatacept | 35 | $187,664 |
| Humira(Cf)Adalimumab | 24 | $176,480 |
| SimponiGolimumab | 28 | $167,974 |
| Humira PenAdalimumab | 21 | $142,255 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 19 | $139,318 |
| Actemra ActpenTocilizumab | 31 | $136,802 |
| BenlystaBelimumab | 24 | $114,658 |
| Cosentyx Unoready PenSecukinumab | 12 | $88,018 |
| Enbrel MiniEtanercept | 12 | $87,698 |
| XeljanzTofacitinib Citrate | 14 | $80,701 |
| Hydroxychloroquine Sulfate | 1,124 | $78,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $82,557 | $774,024114 claims |
| AmgenEnbrel, Otezla | $3,030 | $259,63139 claims |
| Johnson & JohnsonSimponi | $4,735 | $167,97428 claims |
| GSKBenlysta | $33,648 | $114,65824 claims |
| PfizerXeljanz | $525 | $80,70114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in Grand Rapids
- Zhe LiangGrand Rapids$41K
- Mohamed MohamedGrand Rapids$11K
- Brett CapelGrand Rapids$9K
- John FlemingGrand Rapids$9K
- Nour ZleikGrand Rapids$8K
- Saja AlmaaitahGrand Rapids$8K
- Richard MartinGrand Rapids$8K
- Amar MajjhooSaint Clair Shores$1.8M
- Andrew SulichSaint Clair Shores$1.7M
- Dinesh KhannaAnn Arbor$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.